United States Patent:  6,106,859

Appl. No.:  227648

The present invention provides a liposomal aerosol composition, comprising a pharmaceutical compound, a cationic lipid, (c) a neutral co-lipid; and (d) tryptone. Also provided is a nebulized cationic lipid:DNA suspension useful for lipid-DNA transfections, wherein said cationic lipid is bis(guanidinium)-tren-cholesterol.

SUMMARY OF THE INVENTION

In one embodiment of the present invention, there is provided a liposomal aerosol composition, comprising: (1) a pharmaceutical compound, (2) a cationic lipid, (3) a neutral co-lipid, and (4) tryptone.

In another embodiment of the present invention, there is provided a liposomal aerosol composition, comprising: (1) a pharmaceutical compound; (2) a cationic lipid, (3) a neutral co-lipid, and (4) glutamic acid.

In yet another embodiment of the present invention, there is provided a nebulized cationic lipid:co-lipid:DNA suspension useful for lipid-DNA transfections, wherein said cationic lipid is bis(guanidinium)-tren-cholesterol (BGTC).

In still yet another embodiment of the present invention, aerosol exposure was made more efficient and more effective by holding mice in a closed chamber and exposing to aerosol that was replenished during a one minute period of nebulization out of each minutes period. In this design, compressed air containing 5% carbon dioxide was used instead of room air in order to enhance the deep breathing of animals and thereby enhance the lung deposition of the transfection formulations.

Claim 1 of 3 Claims

1. A liposomal aerosol composition, comprising:

(a) a plasmid DNA containing a gene;

(b) a cationic lipid;

(c) a neutral co-lipid; and

(d) tryptone.

____________________________________________
If you want to learn more about this patent, please go directly to the U.S. Patent and Trademark Office Web site to access the full patent.